[1] Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68:394–424. https://doi.org/10.3322/caac.21492.
[2] Yeung RH, Chapman TR, Bowen SR, Apisarnthanarax S (2017) Proton beam therapy for hepatocellular carcinoma Expert Rev Anticancer Ther 17:911–24. https://doi.org/10.1080/14737140.2017.1368392.
[3] Takayasu K, Muramatsu Y, Shima Y, Goto H, Moriyama N, Yamada T, et al (1986) Clinical and radiologic features of hepatocellular carcinoma originating in the caudate lobe Cancer 58:1557–62. https://doi.org/10.1002/1097-0142(19861001)58:7<1557::aid-cncr2820580729>3.0.co;2-e.
[4] Tanaka S, Shimada M, Shirabe K, Maehara SI, Tsujita E, Taketomi A, et al (2005) Surgical outcome of patients with hepatocellular carcinoma originating in the caudate lobe. Am J Surg 190:451–5. https://doi.org/10.1016/j.amjsurg.2004.12.005.
[5] Yamamoto T, Kubo S, Shuto T, Ichikawa T, Ogawa M, Hai S, et al (2004) Surgical strategy for hepatocellular carcinoma originating in the caudate lobe. Surgery 135:595–603. https://doi.org/10.1016/j.surg.2003.10.015.
[6] Yang MC, Lee PH, Sheu JC, Lai MY, Hu RH, Wei CK (1996) Surgical treatment of hepatocellular carcinoma originating from the caudate lobe. World J Surg 20:562–6. https://doi.org/10.1007/s002689900087.
[7] Ikegami T, Ezaki T, Ishida T, Aimitsu S, Fujihara M, Mori M (2004) Limited hepatic resection for hepatocellular carcinoma in the caudate lobe. World J Surg 28:697–701. https://doi.org/10.1007/s00268-004-7341-4.
[8] Hawkins WG, DeMatteo RP, Cohen MS, Jarnagin WR, Fong Y, D’Angelica M, et al (2005) Caudate hepatectomy for cancer: A single institution experience with 150 patients. J Am Coll Surg 200:345–52. https://doi.org/10.1016/j.jamcollsurg.2004.10.036.
[9] Chaib E, Ribeiro MAF Jr, de S Collet e Silva F, Saad WA, Cecconello I (2007) Surgical approach for hepatic caudate lobectomy: Review of 401 cases. J Am Coll Surg 204:118–27. https://doi.org/10.1016/j.jamcollsurg.2006.09.020.
[10] Sakoda M, Ueno S, Kubo F, Hiwatashi K, Tateno T, Kurahara H, et al (2009) Surgery for hepatocellular carcinoma located in the caudate lobe. World J Surg 33:1922–6. https://doi.org/10.1007/s00268-009-0110-7.
[11] Nagasue N, Kohno H, Yamanoi A, Uchida M, Yamaguchi M, Tachibana M, et al (1997) Resection of the caudate lobe of the liver for primary and recurrent hepatocellular carcinomas. J Am Coll Surg 184:1–8.
[12] Takayama T, Makuuchi M (1998) Segmental liver resections, present and future-caudate lobe resection for liver tumors. Hepatogastroenterology 45:20–3.
[13] Peng SY, Li JT, Liu Y Bin, Cai XJ, Mou YP, Feng XD, et al (2006) Surgical treatment of hepatocellular carcinoma originating from caudate lobe--a report of 39 cases. J Gastrointest Surg 10:371–8. https://doi.org/10.1016/j.gassur.2005.09.026.
[14] Liu B, Long J, Wang W, Huang T, Xie X, Chen S, et al (2019) Predictive factors of treatment outcomes after percutaneous ablation of hepatocellular carcinoma in the caudate lobe: A retrospective study. BMC Cancer 19:699. https://doi.org/10.1186/s12885-019-5881-0.
[15] Terayama N, Miyayama S, Tatsu H, Yamamoto T, Toya D, Tanaka N, et al (1998) Subsegmental transcatheter arterial embolization for hepatocellular carcinoma in the caudate lobe. J Vasc Interv Radiol 9:501–8. https://doi.org/10.1016/s1051-0443(98)70307-0.
[16] Miyayama S, Yamashiro M, Yoshie Y, Nakashima Y, Ikeno H, Orito N, et al (2010) Hepatocellular carcinoma in the caudate lobe of the liver: Variations of its feeding branches on arteriography. Jpn J Radiol 28:555–62. https://doi.org/10.1007/s11604-010-0471-8.
[17] Takahashi H, Mori K, Sekino Y, Okumura T, Hiyama T, Fukuda K, et al (2019) Angiographic findings in patients with hepatocellular carcinoma previously treated using proton beam therapy. J Oncol 2019:4–10. https://doi.org/10.1155/2019/3580379.
[18] Wang PM, Chung NN, Hsu WC, Chang FL, Jang CJ, Scorsetti M (2015) Stereotactic body radiation therapy in hepatocellular carcinoma: Optimal treatment strategies based on liver segmentation and functional hepatic reserve. Reports Pract Oncol Radiother 20:417–24. https://doi.org/10.1016/j.rpor.2015.03.005.
[19] Bortfeld T, Schlegel W (1996) An analytical approximation of depth - dose distributions for therapeutic proton beams for therapeutic proton beams. Phys Med Biol 41:1331. https://doi.org/10.1088/0031-9155/41/8/006
[20] Lawrence JH, Tobias CA, Born JL, Linfoot JA, Kling RP, Gottschalk A (1964) Alpha and proton heavy particles and the Bragg Peak in Therapy. Trans Am Clin Clim Assoc 75:111–6.
[21] Mizumoto M, Oshiro Y, Okumura T, Fukumitsu N, Numajiri H, Ohnishi K, et al (2016) Proton beam therapy for hepatocellular carcinoma: A review of the University of Tsukuba Experience. Int J Part Ther 2:570–8. https://doi.org/10.14338/ijpt-15-00035.2.
[22] Kawashima M, Furuse J, Nishio T, Konishi M, Ishii H, Kinoshita T, et al (2005) Phase II study of radiotherapy employing proton beam for hepatocellular carcinoma. J Clin Oncol 23:1839–46. https://doi.org/10.1200/JCO.2005.00.620.
[23] Fukumitsu N, Sugahara S, Nakayama H, Fukuda K, Mizumoto M, Abei M, et al (2009) A prospective study of hypofractionated proton beam therapy for patients with hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 74:831–6. https://doi.org/10.1016/j.ijrobp.2008.10.073.
[24] Mizumoto M, Okumura T, Hashimoto T, Fukuda K, Oshiro Y, Fukumitsu N, et al (2011) Proton beam therapy for hepatocellular carcinoma: A comparison of three treatment protocols. Int J Radiat Oncol Biol Phys 81:1039–45. https://doi.org/10.1016/j.ijrobp.2010.07.015.
[25] Sanford NN, Pursley J, Noe B, Yeap BY, Goyal L, Clark JW, et al (2019) Protons versus photons for unresectable hepatocellular carcinoma: Liver decompensation and overall survival. Int J Radiat Oncol Biol Phys 105:64–72. https://doi.org/10.1016/j.ijrobp.2019.01.076.
[26] Cheng JY, Liu CM, Wang YM, Wang YM, Hsu HC, Huang EY, et al (2020) Proton versus photon radiotherapy for primary hepatocellular carcinoma: a propensity-matched analysis. Radiat Oncol15:1–10. https://doi.org/10.1186/s13014-020-01605-4.
[27] Sugahara S, Nakayama H, Fukuda K, Mizumoto M, Tokita M, Abei M, et al (2009) Proton-beam therapy for hepatocellular carcinoma associated with portal vein tumor thrombosis. Strahlenther Onkol 185:782–8. https://doi.org/10.1007/s00066-009-2020-x.
[28] Lee SU, Park JW, Kim TH, Kim YJ, Woo SM, Koh YH, et al (2014) Effectiveness and safety of proton beam therapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis. Strahlenther Onkol 190:806–14. https://doi.org/10.1007/s00066-014-0604-6.
[29] Mizumoto M, Tokuuye K, Sugahara S, Hata M, Fukumitsu N, Hashimoto T, et al (2007) Proton beam therapy for hepatocellular carcinoma with inferior vena cava tumor thrombus: Report of three cases. Jpn J Clin Oncol 37:459–62. https://doi.org/10.1093/jjco/hym038.
[30] Sekino Y, Okumura T, Fukumitsu N, Iizumi T, Numajiri H, Mizumoto M, et al (2020) Proton beam therapy for hepatocellular carcinoma associated with inferior vena cava tumor thrombus. J Cancer Res Clin Oncol 146:711–20. https://doi.org/10.1007/s00432-019-03096-7.
[31] Chung Y-K, Hwang S, Ko G-Y, Yoon SM (2018) Long-term complete response after transcatheter arterial chemoembolization and stereotactic body radiation therapy in a patient with hepatocellular carcinoma at the caudate lobe. Ann Hepato-Biliary-Pancreatic Surg 22:274. https://doi.org/10.14701/ahbps.2018.22.3.274.
[32] Fukumitsu N, Ishida M, Terunuma T, Mizumoto M, Hashimoto T, Moritake T, et al (2012) Reproducibility of image quality for moving objects using respiratory-gated computed tomography: A study using a phantom model. J Radiat Res 53:945–53. https://doi.org/10.1093/jrr/rrs039.
[33] Inada T, Hayakawa Y, Ohara K, Maruhashi A, Hiramatsu Y, Akisada M (1983) High energy proton beam for the management of cancer [Article in Japanese]. Nihon Igaku Hoshasen Gakkai Zasshi 43:781–93.
[34] Liu P, Yang JM, Niu WY, Kan T, Xie F, Li DQ, et al (2010) Prognostic factors in the surgical treatment of caudate lobe hepatocellular carcinoma. World J Gastroenterol 16:1123–8. https://doi.org/10.3748/wjg.v16.i9.1123.
[35] Abdel Wahab M, Fathy O, Elhanafy E, Atif E, Sultan AM, Salah T, et al (2011) Caudate lobe resection for hepatocellular carcinoma. Hepatogastroenterology 58:1904–8. https://doi.org/10.5754/hge11324.
[36] Sakamoto Y, Nara S, Hata S, Yamamoto Y, Esaki M, Shimada K, et al (2011) Prognosis of patients undergoing hepatectomy for solitary hepatocellular carcinoma originating in the caudate lobe. Surgery 150:959–67. https://doi.org/10.1016/j.surg.2011.03.005.
[37] Nishigaki Y, Tomita E, Hayashi H, Suzuki Y, Iritani S, Kato T, et al (2013) Efficacy and safety of radiofrequency ablation for hepatocellular carcinoma in the caudate lobe of the liver. Hepatol Res 43:467–74. https://doi.org/10.1111/j.1872-034X.2012.01095.x.
[38] Lencioni RA, Allgaier HP, Cioni D, Olschewski M, Deibert P, Crocetti L, et al (2003) Small hepatocellular carcinoma in cirrhosis: randomized comparison of radio-frequency thermal ablation versus percutaneous ethanol injection. Radiology 228:235–40. https://doi.org/10.1148/radiol.2281020718.
[39] Peng ZW, Liang HH, Chen MS, Zhang YJ, Li JQ, Zhang YQ, et al (2008) Percutaneous radiofrequency ablation for the treatment of hepatocellular carcinoma in the caudate lobe. Eur J Surg Oncol 34:166–72. https://doi.org/10.1016/j.ejso.2007.08.004.
[40] Liu B, Long J, Wang W, Huang G, Jiang C, Zhang X, et al (2018) Treatment of hepatocellular carcinoma in the caudate lobe: US-guided percutaneous radiofrequency ablation combined with ethanol ablation. Clin Radiol 73:647–56. https://doi.org/10.1016/j.crad.2018.02.017.
[41] Shibata T, Maetani Y, Ametani F, Kubo T, Itoh K, Konishi J (2002) Efficacy of nonsurgical treatments for hepatocellular carcinoma in the caudate lobe. Cardiovasc Intervent Radiol 25:186–92. https://doi.org/10.1007/s00270-001-0111-x.
[42] Lu CL, Wu JC, Chiang JH, Lui WY, Chau GY, Lee SD (1997) Hepatocellular carcinoma in the caudate lobe: Early diagnosis and active treatment may result in long-term survival. J Gastroenterol Hepatol 12:144–8. https://doi.org/10.1111/j.1440-1746.1997.tb00397.x.
[43] Lee BC, Liu KL, Wu CH, Huang KW, Ho CM, Hu RH, et al (2018) Comparison of radiofrequency ablation and transarterial chemoembolization for hepatocellular carcinoma in the caudate lobe. Cardiovasc Intervent Radiol 41:1699–707. https://doi.org/10.1007/s00270-018-1978-0.
[44] Kudo M, Izumi N, Kubo S, Kokudo N, Sakamoto M, Shiina S, et al (2020) Report of the 20th Nationwide follow-up survey of primary liver cancer in Japan. Hepatol Res 50:15–46. https://doi.org/10.1111/hepr.13438.
[45] Kim H-C, Chung JW, Jae HJ, Yoon J-H, Lee J-H, Kim YJ, et al (2010) Caudate lobe hepatocellular carcinoma treated with selective chemoembolization. Radiology 257:278–87. https://doi.org/10.1148/radiol.10100105.